combretastatin A4 phosphate
information and resources from the National Cancer Institute
combretastatin A4 phosphate
A water-soluble prodrug derived from the African bush willow (Combretum caffrum) with tumor vascular-targeting activity. In vivo, combretastatin A4 phosphate is dephosphorylated to its active metabolite, combretastatin A4, which binds to tubulin and inhibits microtubule depolymerization, resulting in morphological changes in proliferating endothelial cells. As a result, the permeability of tumor vasculature is increased, leading to reduced tumor blood flow and ischemic necrosis of tumor tissue. In vitro, combretastatin A4 phosphate has been shown to be directly cytotoxic to proliferating endothelial cells and tumor cells. combretastatin A4 phosphate
A water-soluble prodrug derived from the African bush willow (Combretum caffrum) with tumor vascular-targeting activity. In vivo, combretastatin A4 phosphate is dephosphorylated to its active metabolite, combretastatin A4, which binds to tubulin and inhibits microtubule depolymerization, resulting in morphological changes in proliferating endothelial cells. As a result, the permeability of tumor vasculature is increased, leading to reduced tumor blood flow and ischemic necrosis of tumor tissue. In vitro, combretastatin A4 phosphate has been shown to be directly cytotoxic to proliferating endothelial cells and tumor cells.
|
|
|
|
news articles
New Patent Awarded for OXiGENE's Lead Therapeutic Candidate ... Mar 29, 2006
Genetic Engineering News, Patent No. 7,018,987 for novel methods of synthesizing its lead therapeutic candidate, Combretastatin A4 Phosphate (CA4P). The patent ...
OXiGENE to Commence First Ever Oncology Clinical Trial Combining a ... Dec 5, 2005
PR Newswire (press release), ...diseases, today announced that it will initiate a new clinical trial with its lead vascular disrupting compound, Combretastatin A4 Phosphate (CA4P). ...
|
|
